24/7 Market News Snapshot 27 March, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

March 27, 2025

DENVER, Colo., 27 March, 2025 (247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
Today’s trading activity for Plus Therapeutics, Inc. (PSTV) commenced at $1.598, showcasing a positive opening sentiment with a notable increase of 6.46%. Currently, the stock is priced at $1.565, reflecting a slight adjustment. A trading volume of 15.31 million shares has been observed, significantly surpassing the average, indicating strong investor engagement. Upon evaluating this performance, it appears that the stock may find support around its opening price. If it can sustain this volume and overcome various resistance levels, further bullish momentum may be on the horizon. Investors are advised to closely observe price movements, as the inherent volatility of the stock presents both challenges and opportunities amid the current market landscape.

Additionally, for the financial year ending December 31, 2024, Plus Therapeutics has reported promising results and notable strategic milestones. The company successfully raised $15 million through private placement financing, ensuring compliance with Nasdaq’s equity requirements and extending its operational capacity until 2026. Also noteworthy is the $2 million advance grant received from the Cancer Prevention and Research Institute of Texas (CPRIT), aimed at advancing the development of its lead drug, REYOBIQ, which targets leptomeningeal metastases.

Dr. Marc H. Hedrick, President, and CEO, expressed optimism about the previous year’s progress, highlighting significant safety and efficacy findings for REYOBIQ. Key achievements include FDA agreement on the drug’s branding and vital Phase 1 trial results published in Nature Communications, indicating favorable median overall survival rates for recurrent glioblastoma patients compared to standard care. Moreover, the company anticipates the launch of its CNSide diagnostic platform in 2025 and plans for presentations at upcoming conferences that will cover advancements in its ReSPECT programs, underlining its commitment to innovation in cancer therapeutics and diagnostics.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.